New plant ramp-up and regulatory approvals may slip
The new hormonal plant's commercial production and WHO/EU GMP approvals are expected only by FY27-end; any delay could push international revenue contribution further out.
CORONA / Q2-FY26 / risks
Keep the risk register visible.
CORONA Remedies · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Productivity of new MR hires may lag
PCPM for reps with 0-3 years experience is only ₹2-2.5 lakh vs. ₹8 lakh for tenured reps; rapid MR addition (5-7% annually) could pressure overall productivity.
Execution risk in entering new therapy areas
Management plans to enter infertility, spine, CNS, etc., but has not provided specific timelines or investment details beyond infertility; competitive intensity may limit success.